July 1 (Bloomberg) -- Onyx Pharmaceuticals, the maker of the cancer drug Nexavar, said it is in contact with other possible acquirers after rejecting an unsolicited $120-a-share cash takeover bid from Amgen Onyx shares surged. Dominic Chu reports on Bloomberg Television's "Market Makers." (Source: Bloomberg)
How Apple Conquered China Market: Bloomberg West (01/30)
Jan. 30 -- Full episode of "Bloomberg West." Guests: GGV Capital's Hans Tung, Strategic Analytics' Neil Mawston, Evercore ISI's Ken Sena, CKE Restaurants CEO Andrew Puzder, Boost VC CEO Adam Draper and Zebra Technologies' Jill Stelfox.
Should Amazon Spin Off Its Growing Cloud Business?
TripAdvisor's Top Pick: Chicago's Langham Hotel
Dan Marino: Roger Goodell Has Done a Really Good Job
Please upgrade your Browser
Your browser is out-of-date. Please download one of these excellent browsers: